Compare TYRA & WOLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | WOLF |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2021 | 2025 |
| Metric | TYRA | WOLF |
|---|---|---|
| Price | $19.70 | $22.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 2 |
| Target Price | ★ $47.45 | $24.00 |
| AVG Volume (30 Days) | 577.7K | ★ 2.7M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,385,982,000.00 |
| Revenue This Year | N/A | $14.87 |
| Revenue Next Year | N/A | $4.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.00 |
| 52 Week Low | $15.94 | $13.49 |
| 52 Week High | $40.65 | $80.82 |
| Indicator | TYRA | WOLF |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 45.06 |
| Support Level | $18.46 | $19.36 |
| Resistance Level | $22.69 | $26.70 |
| Average True Range (ATR) | 1.19 | 2.32 |
| MACD | -0.10 | 0.14 |
| Stochastic Oscillator | 12.33 | 42.84 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.